• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Scopus
  4. Subnanomolar MAS-related G protein-coupled receptor-X2/B2 antagonists with efficacy in human mast cells and disease models
 
  • Details
  • Full
Options
2025
Journal Article
Title

Subnanomolar MAS-related G protein-coupled receptor-X2/B2 antagonists with efficacy in human mast cells and disease models

Abstract
The MAS-related G protein-coupled receptor-X2 (MRGPRX2), an orphan receptor expressed on mast cells (MCs), is upregulated upon inflammation and induces hypersensitivity and inflammatory diseases. In contrast to the large number of MRGPRX2 agonists, only a few antagonists have been described, and no optimization has been reported to improve potency, selectivity, and drug-like properties. Antagonists with ancillary inhibition of the putative mouse ortholog MRGPRB2 have not been described. Here, we present a multi-disciplinary approach involving chemistry, biology, and computational science, resulting in the development of a small-molecule MRGPRX2 antagonist (PSB-172656, 3-ethyl-7,8-difluoro-2-isopropylbenzo[4,5]imidazo [1,2-a] pyrimidin-4(1H)-one) based on a fragment screening hit. The compound exhibits metabolic stability, low cytotoxicity, and competitive blockade of MRGPRX2 activation induced by a diverse range of agonists. It displays subnanomolar potency in Ca<sup>2+</sup> mobilization assays (K<inf>i</inf> value 0.142 nM) and was found to block MRGPRX2-mediated Gα<inf>q</inf> and Gα<inf>i1</inf> dissociation, in addition to β-arrestin-2 recruitment. PSB-172656 is selective for MRGPRX2 versus all other MRGPRX subtypes. Its effect on MCs was confirmed in cell lines, including rat basophilic leukemia cells (RBL-2H3) recombinantly expressing human MRGPRX2, human Laboratory of Allergic Diseases 2 (LAD2) MCs, and native human skin MCs. PSB-172656 was found to additionally block the putative mouse ortholog of MRGPRX2, MRGPRB2, as determined in Ca<sup>2+</sup> mobilization assays (K<inf>i</inf> 0.302 nM), and to prevent mouse tracheal contractions, local allergic reactions, and systemic anaphylactic symptoms. PSB-172656 constitutes a unique pharmacological tool and has the potential to be developed as a drug for mast cell-mediated hypersensitivity reactions and chronic inflammatory diseases, addressing a huge unmet medical need.
Author(s)
Al Hamwi, Ghazl
Universität Bonn
Alnouri, Mohamad Wessam
Universität Bonn
Verdonck, Sven
Rega Institute for Medical Research
Leonczak, Piotr
Rega Institute for Medical Research
Chaki, Shaswati
University of Pennsylvania School of Dental Medicine
Frischbutter, Stefan
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP  
Kolkhir, Pavel
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP  
Matthey, Michaela
Medizinische Fakultät der Ruhr-Universität Bochum
Kopp, Constantin
Universität Bonn
Bednarski, Marek
Jagiellonian University Medical College
Riedel, Yvonne K.
Universität Bonn
Marx, Daniel
Universität Bonn
Clemens, Sophie
Universität Bonn
Namasivayam, Vigneshwaran
Universität Bonn
Gattner, Susanne
Universität Bonn
Thimm, Dominik
Universität Bonn
Sylvester, Katharina
Universität Bonn
Wolf, Katharina
Friedrich-Alexander-Universität Erlangen-Nürnberg
Kremer, Andreas Emanuel
Friedrich-Alexander-Universität Erlangen-Nürnberg
Jonghe, Steven de
Rega Institute for Medical Research
Wenzel, Daniela
Medizinische Fakultät der Ruhr-Universität Bochum
Kotańska, Magdalena
Jagiellonian University Medical College
Ali, Hydar
University of Pennsylvania School of Dental Medicine
Herdewijn, Piet A.M.M.
Rega Institute for Medical Research
Müller, Christa Elisabeth
Universität Bonn
Journal
Signal transduction and targeted therapy  
Open Access
DOI
10.1038/s41392-025-02209-8
Additional full text version
Landing Page
Language
English
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP  
  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024